StreetInsider.com News Articles

Form 4 Disc Medicine, Inc. For: Oct 19 Filed by: Bitterman Kevin

Wed, 21 Oct 2026 17:33:00 -0400

si-local-file:///var/storage/secattach/20261021/27217374.html

Form 424B5 Disc Medicine, Inc.

Wed, 21 Oct 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20261021/27217326.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.

Wed, 21 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261021/27217271.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.

Wed, 21 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261021/27217272.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Wed, 21 Oct 2026 17:12:00 -0400

si-local-file:///var/storage/secattach/20261021/27217273.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund XII, L.P.

Wed, 21 Oct 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20261021/27217269.html

Disc Medicine (IRON) PT Raised to $149 at Jefferies

Wed, 21 Oct 2026 16:01:04 -0400

Jefferies analyst Roger Song raised the price target on Disc Medicine (NASDAQ: IRON) to $149.00 (from $128.00) while maintaining a Buy rating.

The analyst comments "We caught up w/ mgmt and discussed w/ investors post-Ph3 (+)/ best-indisease topline from bito, first disease-modifying drug. We are increasingly bullish on Bito's commercial oppt'y w/ ~6-14K tangible pt pool for potential $1-2B opp'y. We see high POS for pot'l approval by mid'27 after NDA resubmission by YE26. Beyond Bito, IRON will provide data and reg updates for MF anemia program and longer data follow-up for PV program before YE26, likely at ASH'26."

Disc Medicine (IRON) PT Raised to $149 at Jefferies

Wed, 21 Oct 2026 16:01:04 -0400

Jefferies analyst Roger Song raised the price target on Disc Medicine (NASDAQ: IRON) to $149.00 (from $128.00) while maintaining a Buy rating.

Disc Medicine prices $450M stock offering at $75 per share

Tue, 20 Oct 2026 20:52:22 -0400

Disc Medicine, Inc. (NASDAQ: IRON) has priced an upsized underwritten public offering of 6,000,000 shares of common stock at $75.00 per share, according to a company statement.

The offering is expected to generate $450 million in gross proceeds before underwriting discounts, commissions, and other expenses. The company has also granted underwriters a 30-day option to purchase up to an additional 900,000 shares at the offering price.

The offering is expected to close on Oct. 22, 2026, subject to customary closing conditions.

Disc Medicine said it plans to use the net proceeds to fund research and clinical development of its product candidates, support potential

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Tue, 20 Oct 2026 20:52:00 -0400

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,000,000 shares of common stock at a public offering price of $75.00 per share. In addition, Disc has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less underwriting

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

Tue, 20 Oct 2026 20:52:00 -0400

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund I, L.P.

Tue, 20 Oct 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20261020/27211293.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Tue, 20 Oct 2026 17:17:00 -0400

si-local-file:///var/storage/secattach/20261020/27211295.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund XII, L.P.

Tue, 20 Oct 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20261020/27211290.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund X, L.P.

Tue, 20 Oct 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20261020/27211291.html

Disc Medicine (IRON) PT Raised to $115 at Truist Securities

Tue, 20 Oct 2026 09:23:23 -0400

(Updated - October 20, 2026 9:23 AM EDT)

Truist Securities analyst Danielle Brill raised the price target on Disc Medicine (NASDAQ: IRON) to $115.00 (from $83.00) while maintaining a Buy rating.

The analyst commented: "We come away from IRON’s APOLLO topline call increasingly confident in bitopertin’s regulatory and commercial outlook and raise our PT to $115 (was $83). Management views APOLLO as the key missing piece from the prior CRL, supporting YE26 resubmission and a mid-27 FDA decision. While subgroup analyses remain forthcoming, IRON does not expect meaningful differences to alter the study conclusions. Commercially, field work across the top ~100-120 US

Disc Medicine (IRON) PT Raised to $115 at Truist Securities

Tue, 20 Oct 2026 09:23:23 -0400

(Updated - October 20, 2026 9:23 AM EDT)

Truist Securities analyst Danielle Brill raised the price target on Disc Medicine (NASDAQ: IRON) to $115.00 (from $83.00) while maintaining a Buy rating.

Disc Medicine (IRON) PT Raised to $92 at Morgan Stanley

Tue, 20 Oct 2026 08:26:09 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Disc Medicine (NASDAQ: IRON) to $92.00 (from $90.00) while maintaining a Overweight rating.

Disc Medicine (IRON) PT Raised to $170 at Cantor Fitzgerald on Ph3 Results for Bitopertin

Tue, 20 Oct 2026 07:17:53 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Disc Medicine (NASDAQ: IRON) to $170.00 (from $125.00) while maintaining an Overweight rating.

The analyst commented, "Disc Medicine announced the highly anticipated Phase 3 results from APOLLO for bitopertin (oral GlyT1 inhibitor) in EPP/XLP (severe photosensitivity condition). IRON is a Top Pick...We strongly believe the data, which show benefits in both a key surrogate marker and clinical outcome measures, will support a traditional approval, as recall the company aligned with the FDA during a Type A meeting this year (that if APOLLO was successful, could serve as a basis for a

Disc Medicine (IRON) PT Raised to $170 at Cantor Fitzgerald on Ph3 Results for Bitopertin

Tue, 20 Oct 2026 07:17:53 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Disc Medicine (NASDAQ: IRON) to $170.00 (from $125.00) while maintaining an Overweight rating.

Form 424B5 Disc Medicine, Inc.

Tue, 20 Oct 2026 06:00:00 -0400

si-local-file:///var/storage/secattach/20261020/27205813.html

Disc Medicine (IRON) PT Raised to $124 at Wells Fargo

Tue, 20 Oct 2026 05:01:02 -0400

Wells Fargo analyst Derek Archila raised the price target on Disc Medicine (NASDAQ: IRON) to $124.00 (from $86.00) while maintaining a Overweight rating.

The analyst comments "Shares are trading up +32% vs. XBI's +1% implying a ~$2.2B enterprise value which underappreciates the competitive profile of bito's data in EPP/XLP. As we noted in our first take, we recognize the market debate and broader tape could cap shares, but believe they should be higher than this. For shares to re-rate towards our new PT, solid launch execution and patient start forms will be required early in the launch—we are confident in this,

Disc Medicine (IRON) PT Raised to $124 at Wells Fargo

Tue, 20 Oct 2026 05:01:02 -0400

Wells Fargo analyst Derek Archila raised the price target on Disc Medicine (NASDAQ: IRON) to $124.00 (from $86.00) while maintaining a Overweight rating.

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Opportunity Fund II, L.P.

Mon, 19 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261019/27204494.html

Form 144 Disc Medicine, Inc. Filed by: Atlas Venture Fund XII, L.P.

Mon, 19 Oct 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20261019/27204483.html